{"id":"W3004892473","doi":"10.1016/s1470-2045(20)30076-0","title":"Advancing the systemic therapy of lung cancer: quality or quantity?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Pfizer Canada; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Roche; AstraZeneca","keywords":"Pembrolizumab; Pemetrexed; Medicine; Lung cancer; Oncology; Internal medicine; Chemotherapy; Placebo; Cancer; Immunotherapy; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01708649,0.001133028,0.003286886,0.00127643,0.003992494,0.008539162,0.003207799,0.07351483,0.01119593],"category_scores_gemma":[0.06868775,0.001003894,0.001722159,0.001357028,0.008205133,0.01157463,0.004141378,0.0647549,0.008938723],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008444845,"about_ca_system_score_gemma":0.01228508,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006547839,"about_ca_topic_score_gemma":0.01481462,"domain_scores_codex":[0.9851206,0.00576001,0.001566974,0.001097955,0.005282347,0.001172211],"domain_scores_gemma":[0.9369451,0.04294212,0.003304877,0.001302453,0.007556596,0.007948966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001193676,0.00004908605,0.0002701389,0.0001618292,0.00002902597,0.0002834522,0.00007349116,0.00007408896,0.0001868193,0.008518293,0.9659697,0.02426463],"study_design_scores_gemma":[0.0003239556,0.00009932843,0.0005796094,0.0006136078,0.00004484035,0.0005185838,0.0003210087,0.0005003521,0.0001688781,0.04096909,0.9557736,0.00008721699],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.00004710835,0.003078838,0.00005855699,0.9875432,0.00847399,0.000003358182,0.00002000305,0.000007765708,0.000767191],"genre_scores_gemma":[0.001228851,0.002677192,0.0001960624,0.9414467,0.05243138,0.00001768792,0.00001813446,0.0000148621,0.001969195],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.07351483,"threshold_uncertainty_score":0.09036309,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09466019374412431,"score_gpt":0.4158042709461208,"score_spread":0.3211440772019964,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}